600521 华海药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,128,30719.43%8,308,7208,265,7456,643,5736,485,213
减:营业总成本4,142,62317.43%7,096,9006,635,6946,300,6805,327,599
    其中:营业成本1,948,43413.82%3,288,3383,110,9362,657,1342,352,223
               财务费用35,2701,680.40%137,247(10,833)188,184264,872
               资产减值损失(29,193)311.64%(117,176)(70,604)(13,928)(32,776)
公允价值变动收益(67,208)-22.77%(100,248)5,201299,80848,481
投资收益(14,307)-30.37%(62,652)(75,205)147,151(22,391)
    其中:对联营企业和合营企业的投资收益(14,736)-3.78%(27,700)(42,191)(41,774)(28,228)
营业利润957,48237.96%1,124,5401,547,171868,3991,286,555
利润总额956,42539.53%1,100,3211,508,900786,9281,215,355
减:所得税费用202,07564.75%283,072332,890306,284220,757
净利润754,35034.03%817,2491,176,009480,644994,598
减:非控股权益5,784-196.24%(13,217)8,251(6,891)64,783
股东净利润748,56631.60%830,4661,167,759487,535929,815

市场价值指针
每股收益 (元) *0.52033.33%0.5700.8100.3400.640
每股派息 (元) *----0.2000.2400.1000.200
每股净资产 (元) *5.8387.72%5.2864.925--4.312
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容